XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
   Rofecoxib
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Anti-Inflammatory Channel
subscribe to Anti-Inflammatory newsletter

Latest Research : Pharmacology : Anti-Inflammatory

   DISCUSS   |   EMAIL   |   PRINT
COX 2 Inhibitors for Colorectal Adenoma Prevention Increase Serious Cardiovascular Events
Mar 26, 2005, 14:48, Reviewed by: Dr.

Both studies reported an increased incidence of cardiovascular events, which were in excess of what is tolerable for a prevention trial. Whether or not COX-2 inhibitors will have a role in the treatment of cancer remains to be determined.

 
Researchers affiliated with the Adenoma Prevention with Celecoxib (APC) study have reported that Celebrex® (celecoxib) increased serious cardiovascular events. Similar conclusions were reached by the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial. Both studies were reported in the March 17, 2005 issue of the New England Journal of Medicine.

Cyclooxygenase (COX) is an enzyme that catalyses the synthesis of prostaglandins. COX-1 and COX-2 are the two isoforms, inhibited by nonsteroidal anti-inflamatory drugs (NSAIDs). COX-1 is constitutively expressed in a number of cell types, whereas COX-2 is an inducible enzyme whose expression and activity are up-regulated in response to a variety of cytokines, growth factors, and tumor promoters. Cyclooxygenase 2 (COX-2) is overexpressed in 71% to 85% of CRCs.

Two potent COX-2 inhibitors, Celebrex® and Vioxxx®, are undergoing intense testing in different types of cancers, including colorectal cancer. Current phase II data suggests that COX-2 inhibitors enhance the effects of chemotherapy in patients with metastatic colorectal cancer.

Cox-2 inhibitors have also shown promise in phase II studies for the prevention of recurrent polyps in individuals who had surgical removal of colorectal polyps.

The Celebrex® trial compared a 200mg with a 400mg dose versus placebo in 2,035 patients with a history of colorectal neoplasia. Individuals received drug or placebo for 2.8-3.1 years. Death from cardiovascular causes occurred in 7 of 679 patients on placebo, 16 of 685 receiving 200 mg of Celebrex® and 23 of 671 receiving the 400 mg dose of Celebrex®. Deaths from cardiovascular causes increased from 0.5% in the placebo group to 2.2% in individuals receiving the higher dose of Celebrex®. The effects of Celebrex® appeared dose-related for most endpoints of the study. The hazard of dying was greatest for those with increased risk factors for cardiovascular disease. These findings prompted early discontinuation of this study.

The Vioxx® trial compared 25 mg of Vioxx® to placebo for three years in 2,586 individuals with a history of colorectal adenomas. This study was terminated after an average of 2.4 years. The investigators observed an increased incidence of confirmed thrombotic events, congestive heart failure, pulmonary embolus and cardiac failure in patients receiving Vioxx®. There were 6 deaths in the Vioxx® group and 4 in the placebo group.

Comments: Both studies reported an increased incidence of cardiovascular events, which were in excess of what is tolerable for a prevention trial. Whether or not COX-2 inhibitors will have a role in the treatment of cancer remains to be determined.
 

- Solomon SD, McMurray JJV, Pfeiffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England Journal of Medicine. 2005;352:1071-1080. 2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma prevention trial. The New England Journal of Medicine. 2005;352:1092-1101.
 

Cancer Consultants

 
Subscribe to Anti-Inflammatory Newsletter
E-mail Address:

 



Related Anti-Inflammatory News

Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
Ibuprofen - worsening cognitive function
COX 2 inhibitors associated with increased risk of vascular events
Therapeutic prospects beyond COX -2 inhibitors
Ceramide Kinase (CERK) may be a target for new anti-inflammatory drugs
No evidence for greater stomach protection by Cox-2 Inhibitors
European Medicines Agency update on non-selective NSAIDs
NSAIDS and Cox 2 inhibitors increase risk of MI - Study
Eszopiclone Cost Effective in Long-Term Treatment of Insomnia
FDA asks Pfizer to withdraw Bextra and add boxed warning to Celebrex


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us